scispace - formally typeset
D

Daniela Cardinale

Researcher at European Institute of Oncology

Publications -  106
Citations -  11541

Daniela Cardinale is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Cardiotoxicity & Cancer. The author has an hindex of 34, co-authored 91 publications receiving 8375 citations. Previous affiliations of Daniela Cardinale include University of Melbourne & University of Pennsylvania.

Papers
More filters
Journal ArticleDOI

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

TL;DR: The noninvasive evaluation of LVEF has gained importance, and notwithstanding the limitations of the techniques used for its calculation, has emerged as the most widely used strategy for monitoring the changes in cardiac function, both during and after the administration of potentially car- diotoxic cancer treatment.
Journal ArticleDOI

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

TL;DR: Most cardiotoxicity after anthracycline-containing therapy occurs within the first year and is associated with anthrACYcline dose and LVEF at the end of treatment, suggesting early detection and prompt therapy of cardiot toxicity appear crucial for substantial recovery of cardiac function.
Journal ArticleDOI

Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic Therapy

TL;DR: In cancer patients developing AC-CMP, LVEF recovery and cardiac event reduction may be achieved when cardiac dysfunction is detected early and a modern HF treatment is promptly initiated.
Journal ArticleDOI

Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

TL;DR: The non-invasive evaluation of LVEF has gained importance, and notwithstanding the limitations of the techniques used for its calculation, has emerged as the most widely used strategy for monitoring the changes in cardiac function, both during and after the administration of potentially cardiotoxic cancer treatment.
Journal ArticleDOI

Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition

TL;DR: In high-risk, HDC-treated patients, defined by an increased troponin I value, early treatment with enalapril seems to prevent the development of late cardiotoxicity.